Anaplastic Large Cell Lymphoma, ALK-Positive
Information
- Disease name
- Anaplastic Large Cell Lymphoma, ALK-Positive
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03113500 | Active, not recruiting | Phase 2 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | May 25, 2017 | December 21, 2024 |
| NCT02978625 | Active, not recruiting | Phase 2 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | September 27, 2017 | September 1, 2025 |
| NCT02561273 | Completed | Phase 1/Phase 2 | Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma | September 28, 2015 | November 1, 2020 |
| NCT01979536 | Completed | Phase 2 | Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma | November 13, 2013 | March 31, 2024 |
| NCT02419287 | Completed | Phase 2 | Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas | April 2015 | December 2022 |
| NCT03493451 | Completed | Phase 2 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | April 13, 2018 | April 21, 2021 |
| NCT03603847 | Completed | Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma | August 2, 2018 | June 16, 2023 | |
| NCT06176690 | Not yet recruiting | Phase 1 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | June 1, 2024 | June 1, 2043 |
| NCT03505554 | Recruiting | Phase 2 | A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma | October 10, 2017 | December 2024 |
| NCT04925609 | Recruiting | Phase 1/Phase 2 | Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors | August 18, 2022 | December 2030 |
| NCT05978141 | Recruiting | A Registry for People With T-cell Lymphoma | July 27, 2023 | July 27, 2030 | |
| NCT03719898 | Withdrawn | Phase 2 | Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | December 6, 2018 | June 16, 2020 |
| NCT02729961 | Withdrawn | Phase 1/Phase 2 | Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma | January 3, 2018 | July 1, 2023 |
- ICD10 preferred id (Insert disease from ICD10)
- id-SRFSFto-be-added-later-1249018197723-10
- ICD10 class code (Insert disease from ICD10)
- C84.6